

PENDING

A brief position, white paper is in process to describe the shared value discussed here.

- **Oligopolies are not helpful:** Like other services or products, when there are only a handful of companies serving a health or drug market, product prices are high, and there may be supply chain problems resulting in little access to necessary drugs (think insulin), causing death or despair AND higher prices. Maximum Allowable Cost pricing practices have driven most generic manufacturers out of the US where the production cost is lower —and manufacturing standards harder to inspect for quality. Markets only flourish with competition which keeps quality high and costs as low as possible. At the same time, companies have a right to do business at a price above the cost of production. Because of perverse incentives, much of health care is driven by oligopolies where pricing deals are hidden and to the detriment of the end customers.